Study shows GABA, an inexpensive, readily available chemical, may limit impact of COVID-19: On mice 😀

..

The researchers emphasize that unless clinical trials are conducted and GABA is approved for treating COVID-19 by relevant governing bodies, it should not be consumed for the treatment of COVID-19 since it could pose health risks, such as dampening beneficial immune or physiological responses.

..

γ-Aminobutyric acid

γ-Aminobutyric acid, or GABA, is the chief inhibitory neurotransmitter in the developmentally mature mammalian central nervous system. Its principal role is reducing neuronal excitability throughout the nervous system. GABA is sold as a dietary supplement in many countries. Wikipedia

..

This article is a preprint.
Preprints have not been peer reviewed.

.

Study Shows Inexpensive, Readily Available Chemical May Limit Impact of COVID-19

Preclinical studies in mice that model human COVID-19 suggest that an inexpensive, readily available amino acid might limit the effects of the disease.

24-Oct-2022 10:05 AM EDT, by University of California, Los Angeles (UCLA), Health Sciences

Newswise — Preclinical studies in mice that model human COVID-19 suggest that an inexpensive, readily available amino acid might limit the effects of the disease and provide a new off-the-shelf therapeutic option for infections with SARS-CoV-2 variants and perhaps future novel coronaviruses.

A team led by researchers at the David Geffen School of Medicine at UCLA report that an amino acid called GABA, which is available over-the-counter in many countries, reduced disease severity, viral load in the lungs, and death rates in SARS-CoV-2-infected mice. This follows up on their previous finding that GABA consumption also protected mice from another lethal mouse coronavirus called MHV-1. In both cases, GABA treatment was effective when given just after infection or several days later near the peak of virus production. The protective effects of GABA against two different types of coronaviruses suggest that GABA may provide a generalizable therapy to help treat diseases induced by new SARS-CoV-2 variants and novel beta-coronaviruses.  

…Their previous studies showed that GABA administration protected mice from developing severe disease after infection with a mouse coronavirus called MHV-1. To more stringently test the potential of GABA as a therapy for COVID-19, they studied transgenic mice that when infected with SARS-CoV-2 develop severe pneumonia with a high mortality rate. “If our observations of the protective effects of GABA therapy in SARS-CoV-2-infected mice are confirmed in clinical trials, GABA could provide an off-the-shelf treatment to help ameliorate infections with SARS-CoV-2 variants. GABA is inexpensive and stable at room temperature, which could make it widely and easily accessible, and especially beneficial in developing countries.”
.

Working with colleagues at the University of Southern California, the UCLA research team in this study administered GABA to the mice just after infection with SARS-CoV-2, or two days later when the virus levels are near their peak in the mouse lungs. While the vast majority of untreated mice did not survive this infection, those given GABA just after infection, or two days later, had less illness severity and a lower mortality rate over the course of the study. Treated mice also displayed reduced levels of virus in their lungs and changes in circulating immune signaling molecules, known as cytokines and chemokines, toward patterns that were associated with better outcomes in COVID-19 patients. Thus, GABA receptor activation had multiple beneficial effects in this mouse model that are also desirable for the treatment of COVID-19.
.

The researchers emphasize that unless clinical trials are conducted and GABA is approved for treating COVID-19 by relevant governing bodies, it should not be consumed for the treatment of COVID-19 since it could pose health risks, such as dampening beneficial immune or physiological responses.

https://www.newswise.com/coronavirus/study-shows-inexpensive-readily-available-chemical-may-limit-impact-of-covid-19/?article_id=780872&ta=ticker

..


This article is a preprint.

Preprints have not been peer reviewed.
To learn more about preprints in PMC see: NIH Preprint Pilot.

GABA administration prevents severe illness and death following coronavirus infection in mice

Jide Tian, Blake Middleton, and Daniel L. Kaufman

Author information Copyright and License information Disclaimer

This article has been published “GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice” in Viruses.The complete version history of this preprint is available at bioRxiv.

Read the article here:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536896/#:~:text=Together%2C%20the%20reduction%20in%20body,is%20initiated%20after%20symptoms%20appear

..

GABA is an Over The Counter supplement

..

This entry was posted in Uncategorized and tagged . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s